Food Effect Study of Linerixibat Tablets in Healthy Adult Participants

Inclusion criteria: * Overtly healthy male or female participants 18 to 55 years of age inclusive, at the time of signing the informed consent. * Participants' age greater than (\>) 50 years old, must have had at least 3 weeks elapsed after the completion of an approved primary SARS-CoV-2 vaccination course. * Body weight \>50 kg and body mass index (BMI) within the range 18.5 - 32 kilogram per meter square (kg/m2) (inclusive). * Female Participants: * A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: * Is a woman of non-childbearing potential (WONCBP). OR * Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of \<1% per year). * Capable of giving signed informed consent. Exclusion Criteria: * History of cholecystectomy. * Current symptomatic cholelithiasis or inflammatory gall bladder disease. * Significant history of or current disorders capable of significantly altering the absorption, metabolism, or elimination of drugs. * Current clinically significant diarrhea. * History of gastrointestinal surgery with ileal resection or ileal bypass at any time. * Any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. * Administration of any other Ileal Bile Acid Transport (IBAT) inhibitor (including linerixibat) in the 3 months prior to screening. * Past or intended use of over the counter or prescription medication, including vitamins and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme inhibitor) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless approved by the Investigator in conjunction with GSK Medical Monitor. * Current enrollment in a clinical trial or recent participation in a clinical trial and has received an investigational product within the following time period prior to study drug administration: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer). * Exposure to more than 4 new chemical entities within 12 months before the first dose in the current study. * Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5x upper limit of normal (ULN). * Bilirubin \>1.5x ULN (isolated bilirubin \>1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody test or hepatitis C Ribonucleic acid (RNA) test at screening or within 3 months prior to first dose of study intervention. * Positive human immunodeficiency virus (HIV) antibody test * Fridericia's QT correction formula (QTcF) \>450 msec on ECG performed at screening. * Regular use of known drugs of abuse or history of drug abuse or dependence within 6 months of the study. * Regular alcohol consumption within 6 months prior to signing the informed consent. * Regular use of tobacco- or nicotine-containing products in the 3 months prior to screening.